June 24 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL ANNOUNCES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD FOR PIVOTAL PHASE 3 STUDY IN METASTATIC BREAST CANCER
BRIACELL THERAPEUTICS CORP - DSMB IDENTIFIES NO SAFETY CONCERNS, RECOMMENDS CONTINUATION OF BRIA-IMT PHASE 3 STUDY
Source text: ID:nGNX8D26wn
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))